These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 35266828)
21. Ex vivo susceptibility to new antimalarial agents differs among human-infecting Plasmodium species. van Schalkwyk DA; Moon RW; Duffey M; Leroy D; Sutherland CJ Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():5-11. PubMed ID: 34315108 [TBL] [Abstract][Full Text] [Related]
22. Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia. Mbye H; Mane K; Diop MF; Demba MA; Bojang F; Mohammed NI; Jeffries D; Quashie NB; D'Alessandro U; Amambua-Ngwa A J Antimicrob Chemother; 2022 Oct; 77(11):2946-2955. PubMed ID: 35904009 [TBL] [Abstract][Full Text] [Related]
24. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Kaddouri H; Nakache S; Houzé S; Mentré F; Le Bras J Antimicrob Agents Chemother; 2006 Oct; 50(10):3343-9. PubMed ID: 17005815 [TBL] [Abstract][Full Text] [Related]
25. In vivo sensitivity of Plasmodium falciparum to chloroquine, amodiaquine and sulfadoxine-pyrimethamine in western Uganda. Kamugisha J; Kipp W; Burnham G Trop Geogr Med; 1994; 46(6):364-5. PubMed ID: 7892705 [TBL] [Abstract][Full Text] [Related]
26. Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014. Fall B; Madamet M; Camara C; Amalvict R; Fall M; Nakoulima A; Diatta B; Diémé Y; Wade B; Pradines B Emerg Infect Dis; 2016 May; 22(5):841-5. PubMed ID: 27088703 [TBL] [Abstract][Full Text] [Related]
27. Molecular identification and anti-malarial drug resistance profile of Plasmodium falciparum from patients attending Kisoro Hospital, southwestern Uganda. Manirakiza G; Kassaza K; Taremwa IM; Bazira J; Byarugaba F Malar J; 2022 Jan; 21(1):21. PubMed ID: 35033082 [TBL] [Abstract][Full Text] [Related]
28. Agarwal P; Anvikar AR; Pillai CR; Srivastava K Indian J Med Res; 2017 Nov; 146(5):622-628. PubMed ID: 29512604 [TBL] [Abstract][Full Text] [Related]
29. THE EFFICACY OF MARINE NATURAL PRODUCTS AGAINST PLASMODIUM FALCIPARUM. Goto Y; Kamihira R; Nakao Y; Nonaka M; Takano R; Xuan X; Kato K J Parasitol; 2021 Mar; 107(2):284-288. PubMed ID: 33844839 [TBL] [Abstract][Full Text] [Related]
30. Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular Assays. Cooper RA; Conrad MD; Watson QD; Huezo SJ; Ninsiima H; Tumwebaze P; Nsobya SL; Rosenthal PJ Antimicrob Agents Chemother; 2015 Aug; 59(8):5061-4. PubMed ID: 26033725 [TBL] [Abstract][Full Text] [Related]
31. Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation. Sindhe KMV; Wu W; Legac J; Zhang YK; Easom EE; Cooper RA; Plattner JJ; Freund YR; DeRisi JL; Rosenthal PJ mBio; 2020 Jan; 11(1):. PubMed ID: 31992618 [TBL] [Abstract][Full Text] [Related]
32. Slow Clearance of Plasmodium falciparum in Severe Pediatric Malaria, Uganda, 2011-2013. Hawkes M; Conroy AL; Opoka RO; Namasopo S; Zhong K; Liles WC; John CC; Kain KC Emerg Infect Dis; 2015 Jul; 21(7):1237-9. PubMed ID: 26079933 [TBL] [Abstract][Full Text] [Related]
33. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575 [TBL] [Abstract][Full Text] [Related]
34. Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates. Foguim FT; Bogreau H; Gendrot M; Mosnier J; Fonta I; Benoit N; Amalvict R; Madamet M; Wein S; Pradines B; Malar J; 2020 Jun; 19(1):201. PubMed ID: 32503540 [TBL] [Abstract][Full Text] [Related]
35. Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. Marfurt J; Wirjanata G; Prayoga P; Chalfein F; Leonardo L; Sebayang BF; Apriyanti D; Sihombing MAEM; Trianty L; Suwanarusk R; Brockman A; Piera KA; Luo I; Rumaseb A; MacHunter B; Auburn S; Anstey NM; Kenangalem E; Noviyanti R; Russell B; Poespoprodjo JR; Price RN Int J Parasitol Drugs Drug Resist; 2021 Dec; 17():46-56. PubMed ID: 34193398 [TBL] [Abstract][Full Text] [Related]
36. Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda. Flüeck TP; Jelinek T; Kilian AH; Adagu IS; Kabagambe G; Sonnenburg F; Warhurst DC Trop Med Int Health; 2000 Mar; 5(3):174-8. PubMed ID: 10747279 [TBL] [Abstract][Full Text] [Related]
37. Antimalarial activity of Malaria Box Compounds against Plasmodium falciparum clinical isolates. Chirawurah JD; Ansah F; Nyarko PB; Duodu S; Aniweh Y; Awandare GA Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):399-406. PubMed ID: 29128848 [TBL] [Abstract][Full Text] [Related]
38. Detection of Artemisinin Resistance Marker Kelch-13 469Y in Plasmodium falciparum, South Kivu, Democratic Republic of the Congo, 2022. van Loon W; Bisimwa BC; Byela V; Kirby R; Bugeme PM; Balagizi A; Lupande D; Malembaka EB; Mockenhaupt FP; Bahizire E Am J Trop Med Hyg; 2024 Apr; 110(4):653-655. PubMed ID: 38377612 [TBL] [Abstract][Full Text] [Related]
39. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. Baliraine FN; Rosenthal PJ J Infect Dis; 2011 Oct; 204(7):1120-4. PubMed ID: 21881128 [TBL] [Abstract][Full Text] [Related]
40. Ex vivo activity of Proveblue, a methylene blue, against field isolates of Plasmodium falciparum in Dakar, Senegal from 2013-2015. Fall B; Madamet M; Diawara S; Briolant S; Wade KA; Lo G; Nakoulima A; Fall M; Bercion R; Kounta MB; Amalvict R; Benoit N; Gueye MW; Diatta B; Wade B; Pradines B Int J Antimicrob Agents; 2017 Aug; 50(2):155-158. PubMed ID: 28689867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]